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Abstract 
Morphological differentiation between benign
and  malignant  lymphoproliferative  disorders
(LPDs) can be challenging. Immunophenotyping
(IPT)  by  either  technique,  flow  cytometry  or
immunohistochemistry (IHC), is an important
step in solving such difficulty. Thirty-five newly
diagnosed  patients  with  chronic  B-cell  neo-
plasms (11 chronic lymphocytic leukemia, 22 non
Hodgkin lymphoma and 2 hairy cell leukemia)
were included in this study with age range from
20 to 70 years. Monoclonal antibodies surface
expression using lymphoproliferative disorders
panel (CD45, CD19, CD5, CD10, CD11c, CD20,
CD22, CD23, CD38, CD79b, FMC7, CD103, CD25,
kappa and lambda light chains) by flow cytometry
was done on bone marrow samples. CD20, CD5,
CD23, Bcl-2, Bcl-6, kappa and lambda light chain
immunostaining were performed on fixed bone
marrow trephine biopsy specimen. The sensitiv-
ity  of  IHC  was  81.8%  in  chronic  lymphocytic
leukemia (CLL) and 100% in non Hodgkin lym-
phoma (NHL) as regards CD20, 100% in both
groups as regards CD5, 46% in CLL and 66.7% in
NHL as regards CD23, 33.3% in CLL and 50% in
NHL as regards kappa chain, 20% in CLL and
33.3% in NHL as regards lambda chain. We found
that IHC and flow cytometry are equally effective
in diagnosing CLL; however, IHC might be slight-
ly more sensitive than flow cytometry in detect-
ing bone marrow infiltration in NHL and hairy
cell leukemia (HCL).
Introduction
Distinguishing benign and malignant lympho-
proliferative disorders (LPDs) by purely morpho-
logic criteria can be difficult. Immunophenotypic
analysis is a useful adjunct to the morphologic
evaluation of LPDs and is of considerable assis-
tance in resolving difficult diagnostic dilemmas.
The advent of immunophenotyping (IPT) of sam-
ples from patients with LPDs has added much for
proper diagnosis and classification and for better
understanding of the pathogenetic mechanisms
underlying the development of these disorders.1
There are several ways for testing cell mark-
ers, such as flow cytometry in which suspensions
of viable or fixed cells are tested, and immuno-
histochemistry which studies cells in frozen or
paraffin-embedded sections from bone marrow
biopsy specimens or other hemopoietic tissues.2
In immunohistochemistry (IHC), morphology
and antigen label can be visualized simultane-
ously by light microscopy which is not the case in
flow cytometry, enabling accurate identification
of the cells or region of interest.3 It is considered
more suitable in the detection of partial or focal
involvement  by  neoplastic  cells  and  it  is  also
more beneficial in nuclear antigen assessment.4
Another privilege of IHC is the long-term preser-
vation of the biological specimen after process-
ing and the ability to re-examine it at any time.5
The aim of this study was to to identify the
diagnostic  role  of  IHC  in  chronic  B-cell  neo-
plasms  using  a  selected  panel  of  monoclonal
antibodies and to compare this role to that of flow
cytometry.
Materials and Methods
Subjects
This  study  comprised  35  newly  diagnosed
chronic B-cell neoplasms adult patients attend-
ing the hematological unit of clinical pathology
department, Ain Shams University, Cairo, Egypt.
Patients were recruited to the study on the basis
of clinical, laboratory, bone marrow aspirate and
trephine biopsy findings and immunophenotypic
criteria of chronic B-cell neoplasms. Sometimes
lymph nodes biopsy results were provided to con-
firm the diagnosis.
They were 22 males and 13 females with a
male to female ratio 1.7:1.0. Their ages ranged
from 20 to 70 years old with mean of 51 ± 15.2
years. The 35 patients were divided into 3 groups:
chronic lymphocytic leukemia (CLL) group (11
patients), non Hodgkin lymphoma (NHL) group
(22  patients)  and  hairy  cell  leukemia  (HCL)
group (2 patients). The 22 NHL cases comprised
8 mantle cell lymphomas, 6 follicular lymphomas,
5 diffuse large B-cell lymphomas and 3 Burkitt’s
lymphomas.
Patients  were  subjected  to  clinical  sheet
details (with special concern to organomegaly,
lymphadenopathy, fever and weight loss), com-
plete blood count with examination of peripheral
blood smears stained with Leishman stain, bone
marrow aspiration, bone marrow trephine biop-
sy, flow cytometric immunophenotyping for cases
in leukemic phase using lymphoproliferative dis-
orders panel (CD45, CD19, CD5, CD10, CD11c,
CD20, CD22, CD23, CD38, CD79b, FMC7, CD103,
CD25, kappa and lambda light chains). CD20,
CD5, CD23, Bcl-2, Bcl-6, kappa and lambda light
chain immunostaining was performed on fixed
bone marrow trephine biopsy specimen.
Specimens
Two milliliters peripheral blood samples were
collected  in  a  sterile  ethylene-diamine-tetra-
acetic acid (EDTA) containing vaccutainers for
CBC. Bone marrow (BM) aspiration was with-
drawn; the first few drops were spread on glass
slides for morphological examination and 1 mL
into sterile EDTA containing vacutainers for IPT.
For  IPT  by  flow  cytometry  samples  were
processed  within  24  hours.  BM  trephine  core
biopsy was obtained and transferred immediate-
ly in a sterile plastic cup containing aldehyde
solution as a fixative.
Methods
Flow cytometry
Samples  were  processed  using  whole  blood
lysis  method  and  analysis  was  done  using  4
colour flow cytometric analyzer (Coulter EPICS-
XL flow cytometer with system II software) USA.
FCM quality control including alignment, calibra-
tion,  and  color  compensation  was  performed
before sample acquisition according to manufac-
turer’s instructional manual. Samples were dilut-
ed 1:1 with phosphate buffered-saline (PBS), pH
7.4 (Sigma Chemicals, St Louis). The final cell
count suspension was adjusted between 5 and
10ﾥ109/L: 50 uL of each sample was pipetted in
two tubes (one test tube and one control tube); 5
uL of MoAbs fluorescin isothiocyanate (FITC), or
phycoerythrin (PE) labeled (Provided by Coulter
electronics, USA) were added to the test tube
while 5 uL of isotype matched conjugated Igs to
determine the non specific binding were added
to the control tube. Tubes were gently vortexed
and incubated 15 min at room temperature in the
dark. One mL lysing solution was added to each
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tube for 2-5 min and mixed well. At the end 1 mL
PBS was added. Sequential gates were applied;
initially, the lymphoid cells window was defined
by  forward  scatter/side  scatter  and  CD45/side
scatter  patterns.  At  least  20%  of  cells  should
express the marker to be considered positive for
immunophenotyping panel. For all monoclonal
expression both percent positivity and staining
intensity of cells were determined.
Immunohistochemistry
Fixation  was  performed  for  24  hours  then
decalcification of the core was done using disodi-
um EDTA for 48 hours. This was followed by pass-
ing the core in serial concentrations of ethyl alco-
hol (50%, 70%, 85%, 90%, and 100%) ending with
xylene then wax followed by paraffin embedding.
Serial 3-ʼm sections were cut from the paraffin
block, mounted on positively charged slides and
dried  overnight  in  a  60°C  oven.  Depa  -
raffinization in xylene for 24 hours followed by
hydration in descending grades of alcohol; 100%,
90%, 85% and 70% was done. Antigen unmasking
was  done  by  heat  induced  epitope  retrieval
(HIER) method using antigen retrieval solution
(Dako, Denmark) with PH 6.0, for a period of 20
min in a microwave at 800 Watt.
Endogenous peroxidase activity was blocked
by  incubation  of  the  tissue  section  with  3%
hydrogen peroxide in water for 30 min followed
by incubation with the primary monoclonal anti-
body (Dako, Denmark) (Table 1). The strepta-
vidin-biotin method with the horseradish peroxi-
dase enzyme was used as a detection kit (LSAB2,
Dako, Denmark). The sections were then coun-
terstained in Meyer hematoxylin, cover-slipped
by DPX mount media and examined under light
microscope. The positivity of the immunostain-
ing was detected by percentage of positive cells,
intensity  and  pattern  of  staining  (Table  1).
According  to  percentage  of  positive  cells:  four
grades were identified; 0: no reaction, 1+: <5%,
2+:  5-9%,  3+:  10-20%  and  4+:  ≥20%.
Monoclonality was confirmed by either κ/λratios
of more than 3 (κ clone) or less than 0.4 (λ
clone).4
Statictical analysis
Data was analyzed statistically using statisti-
cal  package  for  social  science  (SPSS  version
15.0.1). The following tests were done: descrip-
tive  statistics  including  quantitative  data
(mean±standard  deviation)  for  parametric
results and in the form of median and range in
non parametric ones) and qualitative data (num-
ber and percentage), analytical statistics includ-
ing χ², Fisher’s exact test, Wilcoxon Rank-sum
test (Z-value) and regarding quantitative para-
metric data using Student test (t-value).
Results
In the CLL group (11 patients), the BM aspi-
rate lymphocytes percentage ranged from 40% to
98% with a mean of 82.9%±16.0. In the NHL
cases (22 patients), the BM aspirate lymphocytes
ranged  from  6%  to  92%  with  a  mean  of
24.8%±22.9.  Seven  (31.8%)  cases  of  the  NHL
group had BM lymphocyte count ≥30% (BM infil-
tration), while 13 (59.1%) cases had lymphocyte
count <30%. Dry tap was observed in 2 cases.
Bone marrow trephine biopsy showed lymphocyt-
ic infiltration in all patients. In the CLL group, ten
cases showed diffuse pattern of infiltration with
packed marrow and one case showed interstitial
pattern  of  infiltration  together  with  scattered
nodules of small lymphocytes. In the NHL group,
the predominant pattern of infiltration was the
mixed pattern (8/22, 36.4%), followed by the focal
pattern  (7/22,  31.8%),  the  interstitial  pattern
(4/22,  18.2%)  and  the  diffuse  pattern  (3/22,
13.6%).  In  the  two  HCL  cases,  both  showed
mixed (patchy and interstitial) pattern of infiltra-
tion. 
Flow cytometry
All CLL cases had a score of 4-5 while in the
NHL  group  the  score  was  0-2  according  to
Matutes and Moreau;6,7 immunophenotyping on
BM aspirate was performed in infiltrated cases
which were 7 out of 22 cases (Figures 1, 2).
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Table 1. Monoclonal antibodies. 
Primary Clone Dilution Time of  Grade Pattern of staining
antibody incubation
CD20 L26 Ready to use One hour 4+ Membranous/Cytoplasmic
CD5 CD5/54/F6 Ready to use One hour 3+ Membranous/Cytoplasmic
CD23 MHM6 1:5 One hour 3+ Membranous/Cytoplasmic
Bcl-2 124 Ready to use One hour 4+ Membranous/Cytoplasmic
Bcl-6 PG-B6p 1:10 Overnight at 4ºC 3+ Nuclear
Kappa R10-21-F3 Ready to use Two hours 2+ Perinuclear/Granular cytoplasmic
Lambda N10/2 Ready to use Two hours 2+ Perinuclear/Granular cytoplasmic
All monoclonals were purchased from life trade company Egypt imported from Dako Denmark.
Figure 1. Flow cytometric analysis of a case of chronic lymphocytic leukemia (score=5).[page 8] [Hematology Reports 2012; 4:e3]
In  CLL  group,  all  cases  (100%)  revealed
CD19, CD20 (72.7% of them with dim intensi-
ty),  CD5  and  CD23,  87.5%  expressed  CD22,
67.5% were negative for CD79b, 77.5% were
negative for FMC7 and 35% expressed CD38.
SmIg light chain restriction showed κ restric-
tion in 54.5% and λ in 45.5% of cases. In NHL
group, the lymphocytes expressed pan B cell
markers,  CD19  (100%),  CD20  (100%  with
bright  intensity),  CD22  (85.7%)  and  CD79b
(85.7%,  bright  expression);  CD5  and  CD23
were  expressed  in  3/7  cases  (42.9%);  CD10
was expressed in one case.
Immunohistochemistry
Figures 3-8 show examples of immunohisto-
chemistry  results.  CD20  showed  positivity  in
81.8% (9/11) of the CLL group showing 45.4% of
cases with strong intensity, 18.2% with moder-
ate intensity and 18.2% with weak intensity. In
NHL  group,  positivity  was  detected  in  95.5%
(21/22) of cases showing 45.5% of cases with
strong intensity, 36.4% with moderate intensity
and 13.6% showed weak intensity in NHL group.
Concerning  CD5,  it  was  expressed  in  100%
(11/11)  with  45.5%  showed  strong  intensity,
36.3% with moderate intensity and 18.2% with
weak intensity in CLL group, 50% (11/22) of
cases  showing  22.8%  with  strong  intensity,
18.2%  with  moderate  intensity  and  9%  with
weak intensity in the NHL.
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Figure 2. Flow cytometric analysis of a case of non Hodgkin lymphoma (score=2).
Figure  3.  A  case  of  chronic  lymphocytic
leukemia showing positive CD20.
Figure  4.  A  case  of  chronic  lymphocytic
leukemia showing positive CD5.
Figure  5.  A  case  of  chronic  lymphocytic
leukemia showing positive CD23.
Figure  6.  Light  chain  restriction:  kappa
restriction in a case of chronic lymphocytic
leukemia.
Figure  7.  A  case  of  chronic  lymphocytic
leukemia showing positive Bcl2.
Figure 8. A case of Diffuse large B-cell lym-
phoma showing positive Bcl6.[Hematology Reports 2012; 4:e3]
As regards CD23, it was expressed in 45.5%
(5/11)  showing  9%  with  strong  intensity,  9%
with moderate intensity and 27.5% with weak
intensity and in 13.6% (3/22) of cases of the CLL
group. All cases of NHL showed weak intensity.
Three cases (27.7%) of the CLL group, all of
them had weak intensity and 12/22 (54.5%) of
NHL group showed light chain restriction with
all cases had moderate intensity. As for Bcl-2
protein, it was positive in 54.5% (6/11) & in
36.4%  (8/22)  of  cases  of  the  CLL  and  NHL
groups. Bcl-6 was positive in 13.6% (3/22) of
NHL cases and it was negative in CLL group. 
Comparing immunohistochemistry
to flow cytometry results
The percent positivity of markers and stain-
ing intensity done using IHC were compared to
the percent positivity and to the mean fluores-
cence  intensity  of  these  markers  using  flow
cytometry. In the CLL group, no statistical sig-
nificance  was  found  regarding  all  markers
except for CD20 mean fluorescence intensity
(P=0.002),  however,  within  the  NHL  group,
there  was  a  significant  relation  between  the
percent  positivity  of  both  flow  cytometry  and
IHC regarding CD20 (P=0.01), CD5 (P=0.02),
CD23 (P=0.049), κ(P=0.025) and highly signif-
icant one for λ (P=0.006) (Table 2). The signif-
icant association was restricted to CD20 and
CD5 when comparing their IHC positivity to MFI
by flow cytometry (P=0.002 and 0.04 respective-
ly) (Table 3). On the other hand, comparing the
IHC staining intensity (graded as strong, mod-
erate and weak) to the flow cytometry results
showed  a  high  statistical  significance  as
regards CD5 either its percent positivity or its
MFI (P=0.008, 0.039 respectively). Another sig-
nificance  was  found  regarding  CD20  MFI
(P=0.049).  No  statistical  significance  was
found as regards other markers.
Sensitivity of immunohistochemistry
markers 
The sensitivity of IHC markers was calculat-
ed in both CLL and NHL groups which revealed
a sensitivity of 81.8% for the CLL group and
100% in NHL group as regards CD20, 100% in
both groups as regards CD5, 46% in CLL group
and 66.7% in NHL group as regards CD23, 33.3%
in CLL group and 50% in NHL group as regards
kappa, 20% in CLL group and 33.3% in NHL
group as regards lambda (Table 4).
Discussion
Modern hematopathology relies heavily on
immunophenotyping  both  for  distinguishing
benign from malignant processes as well as for
accurate subclassification. In addition, paraf-
fin section immunophenotyping allows us to
make diagnoses on small biopsies that would
have  previously  been  considered  suspicious
for infiltration. In addition to the numerous
commercially available antibodies, advances in
heat-induced  epitope  retrieval  allow  one  to
obtain  a  detailed  immunophenotype  in  rou-
tinely processed lymphomas that was only pos-
sible  using  flow  cytometry  or  frozen  section
immunostaining.8
Although the use of antibody panels is stan-
dard in flow cytometry, the study of a full panel
of paraffin-reactive antibodies in the workup
of B-cell lymphoid neoplasms is not so preva-
lent. A full immunophenotype and determina-
tion  of  monoclonality  (immunoglobulin  (Ig)
light chain restriction) may be difficult using
IHC because of the destruction of some of the
antigenic epitopes by the fixation and decalci-
fication process used for BMB specimens.9 In
addition, some markers that are useful by flow
cytometry are simply not routinely available for
paraffin IHC.10
The aim of this study was to identify the
diagnostic role of IHC in chronic B-cell neo-
plasms using a selected panel of monoclonal
Article
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Table 2. Comparing percent positivity of immunohistochemistry and flow cytometry in
chronic lymphocytic leukemia and non Hodgkin lymphoma groups.
Marker IHC (No of Flow cytometry P Sig.
positive cases) (% positivity)
CD20 CLL 9 76.9 0.814 NS
NHL 21 49.1 0.01 S
CD5 CLL 11 53.1 0.237 NS
NHL 11 6.3 0.02 S
CD23 CLL 5 67.2 0.118 NS
NHL 3 6.1 0.049 S
Kappa CLL 2 35 0.231 NS
NHL 5 16.8 0.025 S
Lambda CLL 1 2.4 0.251 NS
NHL 7 5.9 0.006 HS
ICH, immunohistochemistry; CCL, chronic lymphocytic leukemia; NHL, non Hodgkin lymphoma; NS, Non-significant; S, Significant; HS, Highly-
significant.
Table 3. Comparing percent positivity of immunohistochemistry and flow cytometry
mean fluorescence intensity in chronic lymphocytic leukemia and non Hodgkin lym-
phoma groups.
Marker IHC (No of Flow cytometry P Sig.
positive cases) (MFI)
CD20 CLL 9 1.77 0.002 HS
NHL 21 20 0.002 HS
CD5 CLL 11 2.69 0.97 NS
NHL 11 0 0.04 S
CD23 CLL 5 1.56 0.3 NS
NHL 30 0.19 NS
Kappa CLL 2 1.1 0.3 NS
NHL 5 1.58 0.5 NS
Lambda CLL 10 0.22 NS
NHL 70 0.45 NS
ICH, immunohistochemistry; CCL, chronic lymphocytic leukemia; NHL, non Hodgkin lymphoma; NS, Non-significant; S, Significant; HS, Highly-
significant.
Table 4. Sensitivity of immunohistochemistry markers in chronic lymphocytic leukemia
and non Hodgkin lymphoma groups.
CLL NHL Total
CD20 81.8% 100% 90%
CD5 100% 100% 100%
CD23 46% 66.7% 50%
Kappa 33.3% 50% 40%
Lambda 20% 33.3% 25%
CCL, chronic lymphocytic leukemia; NHL, non Hodgkin lymphoma.[page 10] [Hematology Reports 2012; 4:e3]
antibodies and to compare this role to that of
flow  cytometry.  Thirty  five  newly  diagnosed
patients having chronic B-LPDs were studied
in the current study; they were classified into
three groups (CLL, NHL and HCL).
Flow  cytometry  on  bone  marrow  aspirate
samples of CLL and infiltrated cases of NHL
and  IHC  were  performed  on  BMB  samples
using a panel of markers: CD20, CD5, CD23,
Bcl2, Bcl6, kappa and lambda light chain. 
Comparing IHC results with flow cytometry,
the current study detected IHC sensitivity 90%,
100%, 50%, 40% and 25% for CD20, CD5, CD23,
kappa and lambda respectively. The sensitivity
of light chain by IHC was 33.3% in CLL and
50% in NHL as regards kappa chain, 20% in
CLL  and  33.3%  in  NHL  as  regards  lambda
chain.
Biesemier  and  his  colleagues11 compared
IHC  fresh  frozen  tissues  to  flow  cytometry.
They  obtained  lower  concordant  results  as
regards  CD20  and  CD5  being  86%  and  80%
respectively.  The  sensitivity  of  light  chain
restriction by IHC was 30% which is near to
that in the present study.
In  a  study  by  El-Sayed  and  colleagues  in
20081 done on Egyptians, they measured the
overall  concordance  between  IHC  and  flow
cytometry without specifying each marker. The
results of the study showed 88% concordance
between  flow  cytometry  and  histopathology/
IHC  in  the  diagnosis  of  lymphoma.  Similar
results  were  obtained  by  Mandacova  et  al.12
and Martinez et al.13 who found a concordance
between  flow  cytometry  and  histopathology/
IHC in 89% and 87.2% of B-lymphoma cases
respectively.
In another study done on Egyptians by Asaad
et al. in 2005,14 they studied CD23 and cyclin
D1 immunostaining of lymph node biopsies in
B-SLL/CLL  and  MCL  cases.  They  found  that
CD23 was positive in 64% of B-CLL/SLL cases
and 4% of MCL cases stained with a membra-
nous pattern of staining. 
In  accordance,  Sah  and  co-workers9 com-
pared the results of flow cytometry, BMB and
aspirates  in  110  patients  with  B-cell  lym-
phomas. In the CLL cases they showed a good
correlation between the three parameters in
over two thirds of samples and up to 88% when
only flow cytometry and IHC were compared.
There  were  very  few  discrepancies  between
flow cytometry and BMB and these were found
mainly in cases with minimal residual disease
(MRD). It seems, according to their study, that
BMB/IHC  and  flow  cytometry  are  the  best
methods to assess MRD in CLL.
Previous  studies  investigating  the  role  of
flow cytometry in detecting BM involvement by
NHL has not provided evidence of much bene-
fit beyond morphological examination alone in
the  biopsy.  Fineberg  et  al.15 and  Dunphy16
found a good correlation (85% and 81% respec-
tively) between morphology on BMB and flow
cytometry, which can be explained in part by
the inclusion of a large number of CLL cases. 
A lower percentage of concordance between
flow  cytometry  and  BMB  was  estimated  by
Naughton et al.17 who reviewed 273 bone mar-
rows from patients known to have NHL, where
flow cytometry detected only 60% of positive
BMB cases.
In our study, using a cut off ≥20%, bcl-2 pro-
tein was positive in 54.5% of CLL cases, 36.4%
of NHL cases (80% of FL, 29% of MCL and 33%
of  Diffuse  large  B-cell  lymphoma  cases).
Indeed,  immunohistochemical  studies  have
shown  that,  beside  FL,  a  broad  spectrum  of
lymphoid malignancies including CLL, plasma
cell  dyscrasia  and  Diffuse  large  B-cell  lym-
phoma  (DLBCL)  also  express  the  bcl-2  pro-
tein.18
Studying  bcl-2  in  lymphoma  cases,
Papakonstantinous  et  al. proved  that  the
expression of bcl-2 protein is not restricted to
B-cell  lymphomas  bearing  the  t(14;  18)
translocation  and  they  showed  the  complete
absence of any correlation between bcl-2 gene
rearrangements  and  bcl-2  expression  in
NHL.19
Despite using the same clone and the same
cut off (20%) as in the current study, Chang et
al.20 found 100% positivity in CLL/SLL cases
(29  cases).  Also  Papakonstantinous  et  al.19
detected 92% positivity in CLL cases. 
Studying  only  Egyptian  patients  with  de
novo  nodal  DLBCL,  Abd  El-Hameed21 found
that positivity for bcl-2 (using a lower cut off
level > 10%) was detected in 60% cases.
In accordance to our results, Kondo et al.22
detected bcl-2 protein by IHC in 75% in FL and
44% in DLBCL. Similarly, Hadzi-Pecova et al.23
found bcl-2 protein expression in 87% of the
patients  with  FL  and  in  38%  of  cases  with
DLBCL. 
Using a lower cut off > 5%, Llanos et al.24
found  95%  of  FL  and  61%  of  DLBCL  cases
expressing  bcl-2  protein  revealing  a  higher
percent than that in this study. Also in a recent
study by Chang et al.,20 they found over 75% of
bcl-2 protein positivity in NHL cases with a cut
off 20%. Within their patients, the bcl-2 per-
cent positivity was 93%, 56% and 100% among
FL (59 cases), DLBCL (77 cases) and MCL (4
cases) respectively.
As for bcl-6, the current study showed posi-
tivity in 13.6% (3/22) of NHL cases and it was
negative in all other groups. Two out of three
cases were DLBCL and one was MCL. 
Despite the small sample size of DLBCL in
the current study, the percent of positive cases
was  in  agreement  with  Lossos  et  al.25 who
showed expression in 63% of DLBCL cases. A
slightly  higher  percent  was  obtained  by
Winter26 (77%) and Colomo27 (72%).
A lower percent in DLBCL was obtained by
Chang28(51%) and Hans29(56%). According to
Winter et al.,26 such differences may represent
the underlying patient population as well as
technical factors related to staining, interpre-
tation, and scoring of positive results.
Authors were contradicting in establishing a
cut  off  value  ranging  from  10-30%.25,27,30-33
These differences may partly be explained by
the differences in the staining techniques, for
instance a study using the EnVision method
and a low cut off of 10%, as much as 97% of
cases were found positive for bcl-6.34
The  aberrant  expression  of  bcl-6  in  MCL
found  in  the  current  study  was  also  experi-
enced by some authors. Only one of 20 MCL
cases studied by Chuang et al.35 expressed bcl-
6. Similarly, Gualco et al.36 found bcl-6 expres-
sion in 12% of the MCL cases.
We  concluded  that  IHC  can  be  a  reliable
alternative  choice  for  IPT  especially  in  NHL
cases. Both IHC and flow cytometry are effec-
tive in diagnosing CLL; however, IHC might be
slightly more sensitive than flow cytometry in
detecting BM infiltration in NHL and HCL.
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